EU Regulator Recommends AstraZeneca Breast Cancer Drug
A European Medicines Agency committee issued a positive opinion on AstraZeneca's camizestrant for breast cancer treatment. The move follows a negative US advisory vote and supports the firm's goal of reaching five billion dollars in peak annual sales for the medicine.
ASTRAZENECA PLC received a positive European regulatory opinion for its breast cancer drug camizestrant, targeting $5 billion in peak annual sales. The recommendation follows a recent rejection by a United States advisory panel over trial design concerns. This approval is critical for the drugmaker to reach its $80 billion revenue target by 2030.
A European Medicines Agency committee adopted the positive opinion on Friday. The decision provides a path for European market entry despite regulatory friction in other regions.
